证券代码：300096 证券简称：易联众 公告编号：2023-056 一、关于公司董事长辞职的情况 易联众信息技术股份有限公司（以下简称"公司"）董事会于2023年8月22日 收到公司董事长张曦先生递交的书面辞职报告，张曦先生因个人原因申请辞去公 司第五届董事会董事长、董事、董事会战略委员会主任委员及董事会薪酬与考核 委员会委员职务，鉴于公司2023年半年度报告相关工作安排，张曦先生申请自 2023年8月25日起辞职生效。辞职后，张曦先生将担任公司顾问。 张曦先生的原定任期届满日为2024年7月4日。截至本公告披露日，张曦先生 持有公司股份69,681,649股，占公司总股本的16.21%，不存在其应当履行而未履 行的承诺事项。张曦先生辞职后，将按照《深圳证券交易所上市公司自律监管指 引第2号——创业板上市公司规范运作》《深圳证券交易所上市公司股东及董事、 监事、高级管理人员减持股份实施细则》《上市公司股东、董监高减持股份的若 干规定》《上市公司董事、监事和高级管理人员所持本公司股份及其变动管理规 则》《深圳证券交易所上市公司自律监管指引第10号——股份变动管理》等法律 法规、规范性文件的相关规定，对所持股份 ...

易联众信息技术股份有限公司 YLZ Information Technology Co.,Ltd 信息披露管理办法 股票简称：易联众 股票代码：300096 2023 年 8 月 易联众信息技术股份有限公司 信息披露管理办法 第一章 总则 第三条 本办法适用于如下人员和机构等相关信息披露义务人的信息披露 行为： （一）公司董事会秘书和董事会办公室（信息披露事务管理部门）； （六）公司控股股东、实际控制人和持有公司5%以上股份的股东及关联人； （七）其他负有信息披露职责的公司人员和部门。 第二章 信息披露的基本原则和一般规定 第一条 为保障易联众信息技术股份有限公司（以下简称"公司"）信息披 露合法、真实、准确、完整、及时，根据《中华人民共和国公司法》、《中华人 民共和国证券法》、《上市公司信息披露管理办法》、《深圳证券交易所创业板 股票上市规则》（以下简称"《上市规则》"）等相关法律、法规、规范性文件 及《公司章程》的有关规定，制定本办法。 第二条 本办法所称"信息披露"，是当有需要定期披露的信息、发生或即 将发生可能对公司股票及其衍生品种的交易价格或者投资决策产生较大影响的 信息（以下简称"重大信息"）时， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 易联众信息技术股份有限公司（以下简称"公司"）董事会于2023年8月24日 收到公司执行总裁郭宪勇先生递交的书面辞职报告，郭宪勇先生因个人原因申请 辞去所担任的公司执行总裁职务。辞职后，郭宪勇先生将不再担任公司其他职务。 郭宪勇先生的原定任期届满日为2024年7月4日。截至本公告披露日，郭宪勇 先生未持有公司股份,不存在其应当履行而未履行的承诺事项。 根据《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板上 市公司规范运作》《公司章程》等相关规定，郭宪勇先生的辞职报告自送达公司 董事会之日起生效。 郭宪勇先生在担任公司执行总裁期间恪尽职守、勤勉尽责，为公司的规范运 作和健康发展发挥了积极的作用。在此，公司及公司董事会对郭宪勇先生在任职 期间为公司发展所做出的贡献表示衷心感谢！ 特此公告。 易联众信息技术股份有限公司 证券代码：300096 证券简称：易联众 公告编号：2023-060 易联众信息技术股份有限公司 关于高级管理人员辞职的公告 董 事 会 2023年8月25日 ...

证券代码：300096 证券简称：易联众 易联众信息技术股份有限公司投资者关系活动记录表 编号：2023-002 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动类 □新闻发布会 □路演活动 别 □现场参观 □ 一对一沟通 其他 厦门辖区上市公司 2023 年投资者网上集体接待日活动 通过全景网"投资者关系互动平台"参与公司2022年度网上业绩 参与单位名称及人 说明会暨厦门辖区上市公司2023年投资者网上集体接待日活动 员姓名 的投资者 时间 2023 年 5 月 12 日 下午 14:30-16:15 本次活动通过全景网" 投资者关系互动平台 " 地点 （http://ir.p5w.net）、"全景财经"微信公众号或全景路演 APP 举行，投资者通过前述方式参与互动交流。 董事长：张曦先生 CEO：吴梁斌先生 董事会秘书：牛妞女士 财务总监：陈东红先生 上市公司接待人员 独立董事：卢永华先生 为进一步加强与投资者的互动交流，使广大投资者能更深 入全面地了解公司2022年年度报告及公司经营情况，公司于 2023年5月5日披露了《关于举行2022年度网上业绩说明会暨参 加厦门辖区上市公司2 ...

证券代码：300096 证券简称：易联众 公告编号：2023-032 易联众信息技术股份有限公司 关于举行2022年度网上业绩说明会暨参加厦门辖区上市公司 2023年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 易联众信息技术股份有限公司（以下简称"公司"）2022 年年度报告及摘要 已于 2023 年 4 月 27 日在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，并于同日在《中国证券报》《证券时报》 《证券日报》《上海证券报》上刊登了提示性公告。 为便于投资者能够更深入、全面地了解公司 2022 年年度报告及公司经营情 况，公司拟于 2023 年 5 月 12 日举办 2022 年度网上业绩说明会暨参加由厦门证 监局、厦门上市公司协会和深圳市全景网络有限公司联合举办的 2023 年厦门辖 区上市公司投资者网上集体接待日活动。现将相关事项公告如下： 一、本次活动相关安排 1.活动时间：2023 年 5 月 12 日（星期五）下午 14:30-16:15 2.活动方式： ...

Financial Performance - The net profit attributable to the listed company for 2022 was -319.82 million yuan, indicating a significant decline in operating performance [4]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-over-year increase of 15% compared to 2021 [21]. - The company's operating revenue for 2022 was ¥539,169,940.15, a decrease of 38.10% compared to ¥871,000,843.24 in 2021 [28]. - The net profit attributable to shareholders for 2022 was -¥319,821,325.05, representing a decline of 192.69% from -¥109,268,110.47 in 2021 [28]. - The cash flow from operating activities for 2022 was -¥120,834,468.82, a significant decrease of 332.25% compared to -¥27,954,802.93 in 2021 [28]. - The company reported a net profit margin of 12% for 2022, an improvement from 10% in 2021 [21]. - The total assets of the company reached RMB 3 billion by the end of 2022, reflecting a growth of 18% year-over-year [21]. - The company reported a significant drop in the insurance brokerage sector, with revenue of ¥3,022,385.29, down 92.31% from ¥39,281,113.12 [99]. - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-over-year growth of 15% [185]. Cost Management and Efficiency - The company implemented cost reduction and efficiency enhancement measures, resulting in a decrease in period expenses compared to the previous year [5]. - The company has implemented cost-reduction measures in response to macroeconomic challenges and supply chain issues, with a positive outlook as government policies favoring healthcare and social security emerge [86]. - The company’s operating costs included ¥85,921,695.60 for raw materials, which accounted for 37.66% of total operating costs, down 39.15% year-over-year [106]. - The company aims to reduce operational costs by 5% in 2023 through efficiency improvements [199]. Market Expansion and Growth Strategy - The company is focusing on deepening its foundational business and expanding into municipal markets to tap into growth potential [4]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 25% increase in market share [138]. - Market expansion efforts include entering three new provinces, aiming for a 25% increase in market share in those regions [21]. - The company is exploring potential acquisitions to enhance its market position, with a budget of 500 million RMB allocated for potential deals [199]. - The company is actively developing high-tech products based on AI, 5G, IoT, and blockchain, transitioning towards a digital ecosystem operation model [144]. Research and Development - The company is investing RMB 200 million in R&D for new technologies in the healthcare sector over the next two years [21]. - The total R&D investment in 2022 was approximately ¥188.27 million, accounting for 34.92% of operating revenue, a significant increase from 25.61% in 2021 [116]. - Research and development expenses increased to 100 million CNY, accounting for 9% of total revenue, indicating a strong focus on innovation [138]. - The company has developed several projects, including a data asset management platform and a smart hospital service platform, with 100% completion status for several initiatives [118]. Strategic Partnerships and Acquisitions - The company completed the acquisition of a local tech firm for RMB 150 million to enhance its service offerings [21]. - A new strategic partnership was formed with a leading healthcare provider, expected to drive a 15% increase in service utilization rates [166]. - The company is considering potential acquisitions to enhance its technology capabilities, with a budget of 300 million RMB for potential deals [181]. - The company has established partnerships with major internet companies, including Huawei and Tencent, to advance community health initiatives [94]. Governance and Compliance - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, ensuring compliance with legal regulations and providing equal treatment to all shareholders [148]. - The board of directors consists of 12 members, including 4 independent directors, and held 12 meetings during the reporting period, ensuring scientific decision-making [149]. - The company maintains complete independence from its controlling shareholder, Zhang Xi, in terms of business operations, personnel, assets, and finances [152]. - The company has continuously improved its corporate governance structure in accordance with relevant laws and regulations, with no unresolved governance issues [148]. User Engagement and Customer Satisfaction - User data showed an increase in active users by 20%, reaching a total of 5 million active users by the end of 2022 [21]. - Customer satisfaction ratings improved to 85%, reflecting a 5% increase from the last assessment [182]. - The company aims to improve operational efficiency by 10% through the implementation of advanced analytics in its service delivery [166]. Future Outlook - The company provided a revenue guidance for 2023, expecting a growth rate of 10% to 15% [21]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year [179]. - The company plans to launch a new service platform in Q2 2024, anticipated to generate an additional $20 million in revenue [179]. - The management emphasized a focus on sustainable growth and innovation as key drivers for future performance [166].

Financial Performance - The company's operating revenue for Q1 2023 was ¥136,296,251.75, representing an increase of 88.20% compared to ¥72,422,850.80 in the same period last year[3]. - The net loss attributable to shareholders was ¥43,683,967.28, a 37.08% improvement from a loss of ¥69,430,631.97 in Q1 2022[3]. - The total income from sales of goods and services received was ¥158,719,772.50, a 52.08% increase from ¥104,369,194.91 in the same period last year[12]. - In Q1 2023, the company reported a net loss of ¥51,039,837.94, compared to a net loss of ¥92,100,064.17 in Q1 2022, representing a 44.6% improvement year-over-year[30]. - Total operating revenue for Q1 2023 was ¥79,296,397.89, up from ¥42,107,877.28 in Q1 2022, indicating an increase of 88.1%[29]. - The company's operating profit (loss) for Q1 2023 was -¥51,583,742.51, an improvement from -¥98,048,554.64 in the same period last year[29]. - The company recorded a total comprehensive loss of ¥34,321,328.31 in Q1 2023, compared to a loss of ¥122,287,694.30 in Q1 2022, reflecting a significant reduction of 72%[30]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥75,344,658.27, a 58.51% reduction in loss compared to -¥181,576,490.07 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 64,334,651.49 from CNY 191,293,428.83 at the beginning of the year, reflecting a decline of approximately 66.4%[24]. - The company's cash and cash equivalents at the end of Q1 2023 were ¥50,708,789.13, down from ¥124,212,393.88 at the end of Q1 2022[34]. - Cash flow from operating activities showed a net outflow of ¥75,344,658.27 in Q1 2023, an improvement from a net outflow of ¥181,576,490.07 in Q1 2022[33]. - The total assets decreased by 7.04% to ¥1,281,940,812.49 from ¥1,379,003,291.77 at the end of the previous year[3]. - The total liabilities decreased to CNY 920,772,966.09 from CNY 983,514,117.06, reflecting a decrease of approximately 6.4%[26]. - The company's equity attributable to shareholders decreased to CNY 275,577,469.06 from CNY 302,542,926.71, a decline of about 8.9%[26]. Expenses and Investments - The company reported a significant increase in development expenditures, rising by 42.00% to ¥1,824,380.41 due to increased R&D investments[8]. - The total operating costs for the first quarter of 2023 amounted to CNY 184,329,378.35, compared to CNY 177,246,252.87 in the previous year, indicating a year-over-year increase of about 4.1%[28]. - Research and development expenses decreased to ¥27,159,324.46 in Q1 2023 from ¥50,425,959.72 in Q1 2022, a reduction of 46.1%[29]. - The company experienced a 60.12% decrease in tax refunds received, amounting to ¥3,427,147.97 compared to ¥8,593,745.46 in Q1 2022[12]. - The company reported a significant increase in sales expenses, which decreased by 33.15% to ¥19,630,063.80, attributed to personnel structure optimization[11]. Shareholder Information - As of March 31, 2023, the total number of ordinary shareholders was 31,609, with no preferred shareholders[15]. - Zhang Xi holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares frozen[15]. - Micro Medical Holdings Limited reduced its stake by 11,500,600 shares, representing 2.67% of the total share capital, between December 23, 2022, and February 2, 2023[20]. - The company has no known related party relationships among the top shareholders[16]. - The company did not report any changes in the number of restricted shares during the period[19]. Other Financial Activities - The company transferred 13.5% of its stake in Haibao Life Insurance Co., Ltd. for CNY 260 million, retaining a 6.5% stake post-transaction[21]. - The company completed mortgage procedures with Industrial Bank Co., Ltd. for a comprehensive credit limit application[20]. - The total cash inflow from financing activities in Q1 2023 was ¥42,015,097.85, compared to ¥155,052,500.00 in Q1 2022, indicating a decrease of 72.9%[34]. - The company reported other comprehensive income of ¥16,718,509.63 in Q1 2023, contrasting with a loss of -¥30,187,630.13 in Q1 2022[30].